Redeye will likely raise its Base Case and forecasts following a strong Q4 report from Hanza, with h...
Redeye updates on Zordix ahead of its Q4-results (due 22 February) and following the company’s annou...
Q4e to show strong growth but slightly weaker margin We trim '23e-'24e adj.
Redeye retains its positive view of Transtema and foresees a strong 2023 fueled by organic and acqui...
Atria will release its Q4 report on 22 February. Price increases and the continued recovery in the r...
8% EBIT miss, but new, forward-leaning 2025 targets Still solid demand: '23e-'24e EBIT up by 15-21% ...
Redeye comments on Jondetech’s Q4 report and its current cash position, which Redeye thinks could la...
Redeye ceases its coverage of Careium due to the end of the contractual period.
Eatgood rapporterade en nettoomsättning om 1,6 MSEK (0,8) i fjärde kvartalet, vilket är en ökning me...
IRLAB Therapeutics has provided an update on upcoming development milestones for its central nervous...
Q4 even better than expected, sales +15% vs cons, EBIT +50% Guides for strong sales growth and order...
Deal with Westinghouse important for Waste Mgmt.First order for SMRs within the F&MT segmentStrong F...
Rekordstarkt Q4 och starkt H2’22 Arcomas omsättning för Q4 uppgick till 41 mkr (21 mkr), motsvarande...
Imponerande lönsamhet och stark tillväxt Omsättningen i kvartalet uppgick till 19,8 mkr vs vårt esti...
Based on Nordea card data for the month of January, Finnish restaurant market nominal growth was up ...
Q4: better than expected driven by both revenues and opex StrongPoint reported Q4 revenues of NOK 40...
Redeye saw a Q4 report showing sales roughly in line with estimates, while costs were slightly highe...
Slower revenue development than expected.
Q4: 1% organic sales growth, adj. EBITA margin of 7.
Marimekko reports its Q4 result on Wednesday, 15th of Feb.
